Integration of Comparative Effectiveness Research into Drug Pricing Frameworks

Contemporary comparative effectiveness research plays a vital role in supporting federal and state drug pricing programs by highlighting real-world benefits, yet persistent challenges and unclear guidance continue to limit its integration. Core principles of evidence evaluation, research question formulation, and population applicability demand more rigorous and transparent application across these initiatives.

Evidence Gaps in Pricing Negotiations

In recently published research, linked below, identifying fit-for-purpose data and ensuring decision-making transparency stood out as urgent priorities during expert discussions. The compressed timeline for Medicare Drug Price Negotiation Program reviews adds further pressure, restricting in-depth analysis of comparative effectiveness research. Prescription Drug Affordability Boards in nine states encounter similar obstacles when weighing clinical findings against costs to set upper payment limits.

Actionable Steps for Stakeholders

Manufacturers can refine evidence packages, bolster scientific credibility, and align submissions with reviewer needs in affordability reviews. These measures help embed contemporary comparative effectiveness research into Maximum Fair Price negotiations and broader cost-management strategies.